In view of the key role of macrophages in cancer immunity, current therapies targeting TAMs utilize four strategies: (1) restricting macrophage recruitment, (2) depleting TAMs, (3) re-educating TAMs, and (4) blocking the CD47-signal regulatory protein alpha (SIRPα) pathway. Here, SIRPA is linked to cancer.